BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20175198)

  • 21. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
    Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
    Shi H; Guo J; Duff DJ; Rahmatpanah F; Chitima-Matsiga R; Al-Kuhlani M; Taylor KH; Sjahputera O; Andreski M; Wooldridge JE; Caldwell CW
    Carcinogenesis; 2007 Jan; 28(1):60-70. PubMed ID: 16774933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation.
    Campo Dell'Orto M; Banelli B; Giarin E; Accordi B; Trentin L; Romani M; te Kronnie G; Basso G
    Oncol Rep; 2007 Aug; 18(2):417-23. PubMed ID: 17611665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
    Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylation of promoter region in p27 gene plays a role in the development of lymphoid malignancies.
    Nakatsuka S; Liu A; Yao M; Takakuwa T; Tomita Y; Hoshida Y; Nishiu M; Aozasa K
    Int J Oncol; 2003 Mar; 22(3):561-8. PubMed ID: 12579309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities.
    Bilanges B; Varrault A; Mazumdar A; Pantaloni C; Hoffmann A; Bockaert J; Spengler D; Journot L
    Oncogene; 2001 Mar; 20(10):1246-53. PubMed ID: 11313869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
    Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
    Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines.
    Ku JL; Kang SB; Shin YK; Kang HC; Hong SH; Kim IJ; Shin JH; Han IO; Park JG
    Oncogene; 2004 Sep; 23(40):6736-42. PubMed ID: 15273736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peroxisome proliferator-activated receptor gamma is a Zac target gene mediating Zac antiproliferation.
    Barz T; Hoffmann A; Panhuysen M; Spengler D
    Cancer Res; 2006 Dec; 66(24):11975-82. PubMed ID: 17178896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor.
    Pang JC; Chang Q; Chung YF; Teo JG; Poon WS; Zhou LF; Kong X; Ng HK
    Hum Pathol; 2005 Jan; 36(1):36-43. PubMed ID: 15712180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses.
    Chung SK; Lee MG; Ryu BK; Lee JH; Han J; Byun DS; Chae KS; Lee KY; Jang JY; Kim HJ; Chi SG
    Gastroenterology; 2007 Jun; 132(7):2459-77. PubMed ID: 17570219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
    Kim YI; Shin MK; Lee JW; Chung JH; Lee MH
    Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
    Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
    Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent epigenetic inactivation of the SLIT2 gene in gliomas.
    Dallol A; Krex D; Hesson L; Eng C; Maher ER; Latif F
    Oncogene; 2003 Jul; 22(29):4611-6. PubMed ID: 12881718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Both gene deletion and promoter hyper-methylation contribute to the down-regulation of ZAC/PLAGL1 gene in gastric adenocarcinomas: a case control study.
    Li Z; Ding Y; Zhu Y; Yin M; Le X; Wang L; Yang Y; Zhang Q
    Clin Res Hepatol Gastroenterol; 2014 Dec; 38(6):744-50. PubMed ID: 25091631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.